| Autor: |
Satomi Shirakaki, Rohini Roy Roshmi, Toshifumi Yokota |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of Personalized Medicine, Vol 13, Iss 1, p 91 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2075-4426 |
| DOI: |
10.3390/jpm13010091 |
| Popis: |
Giant axonal neuropathy (GAN) is a pediatric, hereditary, neurodegenerative disorder that affects both the central and peripheral nervous systems. It is caused by mutations in the GAN gene, which codes for the gigaxonin protein. Gigaxonin plays a role in intermediate filament (IF) turnover hence loss of function of this protein leads to IF aggregates in various types of cells. These aggregates can lead to abnormal cellular function that manifests as a diverse set of symptoms in persons with GAN including nerve degeneration, cognitive issues, skin diseases, vision loss, and muscle weakness. GAN has no cure at this time. Currently, an adeno-associated virus (AAV) 9-mediated gene replacement therapy is being tested in a phase I clinical trial for the treatment of GAN. This review paper aims to provide an overview of giant axonal neuropathy and the current efforts at developing a treatment for this devastating disease. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
